nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—Yawning—Riluzole—amyotrophic lateral sclerosis	0.0319	0.13	CcSEcCtD
Naloxone—CREB1—nerve—amyotrophic lateral sclerosis	0.0252	0.106	CbGeAlD
Naloxone—CREB1—hindbrain—amyotrophic lateral sclerosis	0.0188	0.0796	CbGeAlD
Naloxone—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.0168	0.0685	CcSEcCtD
Naloxone—OPRM1—nerve—amyotrophic lateral sclerosis	0.0136	0.0573	CbGeAlD
Naloxone—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0129	0.0524	CcSEcCtD
Naloxone—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.0128	0.0521	CcSEcCtD
Naloxone—TLR4—cerebellum—amyotrophic lateral sclerosis	0.0121	0.0511	CbGeAlD
Naloxone—CREB1—embryo—amyotrophic lateral sclerosis	0.0118	0.0498	CbGeAlD
Naloxone—Coma—Riluzole—amyotrophic lateral sclerosis	0.0117	0.0479	CcSEcCtD
Naloxone—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.0114	0.0467	CcSEcCtD
Naloxone—CREB1—brainstem—amyotrophic lateral sclerosis	0.0108	0.0456	CbGeAlD
Naloxone—TLR4—brain—amyotrophic lateral sclerosis	0.00982	0.0415	CbGeAlD
Naloxone—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00887	0.0362	CcSEcCtD
Naloxone—CREB1—medulla oblongata—amyotrophic lateral sclerosis	0.00753	0.0318	CbGeAlD
Naloxone—ESR1—hindbrain—amyotrophic lateral sclerosis	0.00742	0.0313	CbGeAlD
Naloxone—Depression—Riluzole—amyotrophic lateral sclerosis	0.00717	0.0292	CcSEcCtD
Naloxone—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00689	0.0281	CcSEcCtD
Naloxone—CREB1—spinal cord—amyotrophic lateral sclerosis	0.00671	0.0284	CbGeAlD
Naloxone—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00642	0.0262	CcSEcCtD
Naloxone—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00599	0.0244	CcSEcCtD
Naloxone—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00585	0.0239	CcSEcCtD
Naloxone—OPRM1—brainstem—amyotrophic lateral sclerosis	0.00582	0.0246	CbGeAlD
Naloxone—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00582	0.0237	CcSEcCtD
Naloxone—Chills—Riluzole—amyotrophic lateral sclerosis	0.00579	0.0236	CcSEcCtD
Naloxone—CREB1—nervous system—amyotrophic lateral sclerosis	0.00566	0.0239	CbGeAlD
Naloxone—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00565	0.0231	CcSEcCtD
Naloxone—Tension—Riluzole—amyotrophic lateral sclerosis	0.00551	0.0225	CcSEcCtD
Naloxone—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00546	0.0223	CcSEcCtD
Naloxone—CREB1—central nervous system—amyotrophic lateral sclerosis	0.00545	0.023	CbGeAlD
Naloxone—CREB1—cerebellum—amyotrophic lateral sclerosis	0.00532	0.0225	CbGeAlD
Naloxone—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00526	0.0215	CcSEcCtD
Naloxone—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00516	0.0211	CcSEcCtD
Naloxone—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00487	0.0199	CcSEcCtD
Naloxone—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00485	0.0198	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00475	0.0194	CcSEcCtD
Naloxone—ESR1—embryo—amyotrophic lateral sclerosis	0.00464	0.0196	CbGeAlD
Naloxone—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.0045	0.0183	CcSEcCtD
Naloxone—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00447	0.0183	CcSEcCtD
Naloxone—OPRD1—nervous system—amyotrophic lateral sclerosis	0.00447	0.0189	CbGeAlD
Naloxone—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00445	0.0182	CcSEcCtD
Naloxone—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00443	0.0181	CcSEcCtD
Naloxone—CREB1—brain—amyotrophic lateral sclerosis	0.00432	0.0183	CbGeAlD
Naloxone—OPRD1—central nervous system—amyotrophic lateral sclerosis	0.00431	0.0182	CbGeAlD
Naloxone—OPRK1—nervous system—amyotrophic lateral sclerosis	0.00429	0.0181	CbGeAlD
Naloxone—ESR1—brainstem—amyotrophic lateral sclerosis	0.00425	0.018	CbGeAlD
Naloxone—OPRK1—central nervous system—amyotrophic lateral sclerosis	0.00413	0.0174	CbGeAlD
Naloxone—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00412	0.0168	CcSEcCtD
Naloxone—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00409	0.0167	CcSEcCtD
Naloxone—OPRK1—cerebellum—amyotrophic lateral sclerosis	0.00403	0.0171	CbGeAlD
Naloxone—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00396	0.0162	CcSEcCtD
Naloxone—Pain—Riluzole—amyotrophic lateral sclerosis	0.00392	0.016	CcSEcCtD
Naloxone—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00362	0.0148	CcSEcCtD
Naloxone—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00362	0.0148	CcSEcCtD
Naloxone—OPRM1—spinal cord—amyotrophic lateral sclerosis	0.00362	0.0153	CbGeAlD
Naloxone—SLCO1A2—medulla oblongata—amyotrophic lateral sclerosis	0.00349	0.0148	CbGeAlD
Naloxone—OPRD1—brain—amyotrophic lateral sclerosis	0.00342	0.0144	CbGeAlD
Naloxone—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00329	0.0134	CcSEcCtD
Naloxone—OPRK1—brain—amyotrophic lateral sclerosis	0.00328	0.0139	CbGeAlD
Naloxone—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00314	0.0128	CcSEcCtD
Naloxone—SLCO1A2—spinal cord—amyotrophic lateral sclerosis	0.00312	0.0132	CbGeAlD
Naloxone—OPRM1—nervous system—amyotrophic lateral sclerosis	0.00305	0.0129	CbGeAlD
Naloxone—OPRM1—central nervous system—amyotrophic lateral sclerosis	0.00294	0.0124	CbGeAlD
Naloxone—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00291	0.0119	CcSEcCtD
Naloxone—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00272	0.0111	CcSEcCtD
Naloxone—SLCO1A2—nervous system—amyotrophic lateral sclerosis	0.00263	0.0111	CbGeAlD
Naloxone—SLCO1A2—central nervous system—amyotrophic lateral sclerosis	0.00253	0.0107	CbGeAlD
Naloxone—SLCO1A2—cerebellum—amyotrophic lateral sclerosis	0.00247	0.0104	CbGeAlD
Naloxone—OPRM1—brain—amyotrophic lateral sclerosis	0.00233	0.00985	CbGeAlD
Naloxone—ESR1—nervous system—amyotrophic lateral sclerosis	0.00223	0.00941	CbGeAlD
Naloxone—ESR1—central nervous system—amyotrophic lateral sclerosis	0.00214	0.00906	CbGeAlD
Naloxone—ESR1—cerebellum—amyotrophic lateral sclerosis	0.0021	0.00886	CbGeAlD
Naloxone—SLCO1A2—brain—amyotrophic lateral sclerosis	0.00201	0.00848	CbGeAlD
Naloxone—ALB—brain—amyotrophic lateral sclerosis	0.002	0.00843	CbGeAlD
Naloxone—ABCB1—embryo—amyotrophic lateral sclerosis	0.00183	0.00774	CbGeAlD
Naloxone—ESR1—brain—amyotrophic lateral sclerosis	0.0017	0.0072	CbGeAlD
Naloxone—CYP2C8—brain—amyotrophic lateral sclerosis	0.0014	0.00593	CbGeAlD
Naloxone—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.00124	0.00525	CbGeAlD
Naloxone—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.0012	0.00506	CbGeAlD
Naloxone—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.00117	0.00495	CbGeAlD
Naloxone—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.00104	0.00441	CbGeAlD
Naloxone—ABCB1—nervous system—amyotrophic lateral sclerosis	0.00088	0.00372	CbGeAlD
Naloxone—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000847	0.00358	CbGeAlD
Naloxone—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000828	0.0035	CbGeAlD
Naloxone—ABCB1—brain—amyotrophic lateral sclerosis	0.000672	0.00284	CbGeAlD
Naloxone—CYP2C8—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000282	0.000544	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000275	0.00053	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000271	0.000522	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.00027	0.00052	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.00027	0.00052	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000268	0.000517	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000267	0.000515	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000267	0.000515	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000263	0.000508	CbGpPWpGaD
Naloxone—ALB—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000262	0.000506	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000262	0.000505	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	0.000256	0.000494	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000254	0.00049	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000252	0.000487	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	0.000252	0.000486	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000252	0.000485	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000251	0.000485	CbGpPWpGaD
Naloxone—CREB1—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000246	0.000475	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000244	0.000471	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—RARA—amyotrophic lateral sclerosis	0.000244	0.00047	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	0.000241	0.000465	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000241	0.000464	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000239	0.000461	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000238	0.00046	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000237	0.000458	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000237	0.000456	CbGpPWpGaD
Naloxone—CREB1—Disease—CST3—amyotrophic lateral sclerosis	0.000231	0.000445	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	0.00023	0.000444	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000227	0.000438	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—GSR—amyotrophic lateral sclerosis	0.000226	0.000435	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000225	0.000434	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000224	0.000433	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000224	0.000433	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	0.000223	0.000431	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—C3—amyotrophic lateral sclerosis	0.000222	0.000428	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000221	0.000426	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000221	0.000425	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000219	0.000423	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000219	0.000423	CbGpPWpGaD
Naloxone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	0.000219	0.000422	CbGpPWpGaD
Naloxone—ALB—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000218	0.00042	CbGpPWpGaD
Naloxone—ALB—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000218	0.00042	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000218	0.00042	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000217	0.000419	CbGpPWpGaD
Naloxone—ALB—Platelet degranulation—VEGFA—amyotrophic lateral sclerosis	0.000214	0.000413	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000214	0.000412	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000213	0.000411	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—C3—amyotrophic lateral sclerosis	0.000213	0.000411	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000211	0.000406	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000208	0.000402	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000207	0.0004	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000205	0.000396	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000204	0.000394	CbGpPWpGaD
Naloxone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—amyotrophic lateral sclerosis	0.000204	0.000393	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000204	0.000393	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000203	0.000392	CbGpPWpGaD
Naloxone—CREB1—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.000203	0.000392	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000203	0.000392	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	0.0002	0.000387	CbGpPWpGaD
Naloxone—ALB—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000199	0.000384	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000199	0.000384	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—MMP9—amyotrophic lateral sclerosis	0.000197	0.00038	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000197	0.000379	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000196	0.000378	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000193	0.000373	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000193	0.000373	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000193	0.000373	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000193	0.000372	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000191	0.000369	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000191	0.000368	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000191	0.000368	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000191	0.000368	CbGpPWpGaD
Naloxone—CREB1—Immune System—ATF1—amyotrophic lateral sclerosis	0.000191	0.000368	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.00019	0.000367	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	0.000189	0.000365	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	0.000189	0.000364	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000186	0.00036	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000186	0.000359	CbGpPWpGaD
Naloxone—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000185	0.000357	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000185	0.000357	CbGpPWpGaD
Naloxone—CREB1—Immune System—CASP9—amyotrophic lateral sclerosis	0.000182	0.00035	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—VEGFA—amyotrophic lateral sclerosis	0.000177	0.000341	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000177	0.000341	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000175	0.000338	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000175	0.000338	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000175	0.000337	CbGpPWpGaD
Naloxone—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000174	0.000336	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000172	0.000332	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000169	0.000327	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000169	0.000327	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000169	0.000326	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000169	0.000326	CbGpPWpGaD
Naloxone—CREB1—Disease—CASP9—amyotrophic lateral sclerosis	0.000168	0.000323	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000167	0.000323	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000166	0.000321	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000165	0.000319	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000162	0.000313	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000161	0.000311	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000161	0.00031	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.00016	0.000309	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000159	0.000308	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	0.000158	0.000306	CbGpPWpGaD
Naloxone—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	0.000158	0.000304	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000155	0.0003	CbGpPWpGaD
Naloxone—CREB1—Immune System—ERBB4—amyotrophic lateral sclerosis	0.000155	0.0003	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000155	0.000299	CbGpPWpGaD
Naloxone—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000154	0.000296	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000153	0.000294	CbGpPWpGaD
Naloxone—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000151	0.000292	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000151	0.000291	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000147	0.000284	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD40LG—amyotrophic lateral sclerosis	0.000146	0.000282	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	0.000145	0.00028	CbGpPWpGaD
Naloxone—CREB1—Disease—ERBB4—amyotrophic lateral sclerosis	0.000143	0.000277	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000143	0.000276	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000143	0.000276	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000143	0.000275	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000141	0.000273	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000141	0.000273	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000141	0.000272	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	0.00014	0.000271	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.00014	0.00027	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	0.000138	0.000266	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000136	0.000262	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000134	0.000258	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000131	0.000254	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000131	0.000253	CbGpPWpGaD
Naloxone—CREB1—Immune System—C3—amyotrophic lateral sclerosis	0.000129	0.000249	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000127	0.000244	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	0.000126	0.000243	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000125	0.000242	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000124	0.000238	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000123	0.000238	CbGpPWpGaD
Naloxone—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000123	0.000237	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000123	0.000237	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00012	0.000232	CbGpPWpGaD
Naloxone—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000119	0.00023	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000119	0.000229	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000118	0.000228	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000118	0.000227	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000118	0.000227	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000117	0.000226	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000117	0.000226	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	0.000116	0.000223	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000115	0.000222	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000115	0.000222	CbGpPWpGaD
Naloxone—CREB1—Disease—APOE—amyotrophic lateral sclerosis	0.000111	0.000214	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	0.000111	0.000214	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.00011	0.000213	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.00011	0.000213	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	0.00011	0.000213	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000108	0.000208	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000108	0.000208	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000105	0.000202	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000104	0.000201	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000103	0.000198	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000101	0.000195	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.0001	0.000194	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.0001	0.000194	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.0001	0.000193	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.0001	0.000193	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.95e-05	0.000192	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	9.71e-05	0.000187	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	9.65e-05	0.000186	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	9.5e-05	0.000183	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.45e-05	0.000182	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.42e-05	0.000182	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	9.4e-05	0.000181	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	9.35e-05	0.00018	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.15e-05	0.000176	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.11e-05	0.000176	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	9.1e-05	0.000176	CbGpPWpGaD
Naloxone—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	9.05e-05	0.000175	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.78e-05	0.000169	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	8.67e-05	0.000167	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	8.61e-05	0.000166	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	8.5e-05	0.000164	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.35e-05	0.000161	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.32e-05	0.000161	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	8.3e-05	0.00016	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	8.26e-05	0.000159	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	8.26e-05	0.000159	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	8.07e-05	0.000156	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	7.93e-05	0.000153	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	7.77e-05	0.00015	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	7.75e-05	0.000149	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7.69e-05	0.000148	CbGpPWpGaD
Naloxone—CREB1—Disease—PTGS2—amyotrophic lateral sclerosis	7.61e-05	0.000147	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—APOE—amyotrophic lateral sclerosis	7.53e-05	0.000145	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	7.49e-05	0.000145	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.42e-05	0.000143	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.3e-05	0.000141	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	7.06e-05	0.000136	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.98e-05	0.000135	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.79e-05	0.000131	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6.58e-05	0.000127	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	6.44e-05	0.000124	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.42e-05	0.000124	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.4e-05	0.000124	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.19e-05	0.000119	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.17e-05	0.000119	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	5.95e-05	0.000115	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.74e-05	0.000111	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	5.69e-05	0.00011	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	5.66e-05	0.000109	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.61e-05	0.000108	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.47e-05	0.000105	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.16e-05	9.95e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.09e-05	9.82e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.94e-05	9.54e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.93e-05	9.51e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	4.89e-05	9.44e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.89e-05	9.43e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	4.88e-05	9.42e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.86e-05	9.38e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.74e-05	9.15e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.67e-05	9.01e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.66e-05	8.98e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.49e-05	8.67e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.47e-05	8.62e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.32e-05	8.34e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.26e-05	8.22e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.21e-05	8.12e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.2e-05	8.09e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.18e-05	8.07e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.08e-05	7.88e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.92e-05	7.55e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	3.7e-05	7.13e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	3.7e-05	7.13e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	3.68e-05	7.09e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.67e-05	7.07e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.65e-05	7.05e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.45e-05	6.66e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.24e-05	6.25e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	3.22e-05	6.21e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.17e-05	6.12e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.16e-05	6.1e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.1e-05	5.98e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.06e-05	5.9e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.77e-05	5.35e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.75e-05	5.3e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.63e-05	5.06e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.53e-05	4.89e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.52e-05	4.86e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.41e-05	4.65e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.34e-05	4.52e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.21e-05	4.26e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.08e-05	4.01e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.98e-05	3.83e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.36e-05	2.62e-05	CbGpPWpGaD
